Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Post-ASH 2025 Lymphoma Highlights

11 February 2026 | Virtual Webinar

Post-ASH 2025 Lymphoma Highlights

11 February 2026 | Virtual Webinar
Post-ASH 2025 Lymphoma Highlights
Featuring presentations & discussions on selected lymphoma abstracts from the 67th ASH Annual Meeting and Exposition
Wednesday 11 February | 10:00 – 12:00 CST/ 16:00 – 18:00 GMT/ 17:00 – 19:00 CET

Chair: Jason Westin | Moderators: Gloria Iacoboni & Laurie Sehn

The Post-ASH 2025 Lymphoma Highlights has been supported by AstraZeneca (Diamond Sponsor), Genentech (Gold Sponsor), Galapagos (Silver Sponsor) and Genmab (Silver Sponsor). Supporters have no influence over the production of content.

Explore the presentations and panel discussions below

 

Recent progress with chemotherapy treatment and outcomes Advances with CAR T-cell therapies  Latest with bispecifics  Developments with additional immunotherapies and targeted therapies 

Session 1: Recent progress with chemotherapy treatment and outcomes

Steven Wang
Longitudinal circulating tumor DNA dynamics during & after first-line therapy in a national cohort of large B-cell lymphomas 
Steven Wang Amsterdam UMC, Amsterdam, Netherlands
Phase II study of lenalidomide and ibrutinib in association with rituximab-methotrexate procarbazine vincristin (R-MPV) as a targeted induction treatment for patients aged 18 to 65 with ND-PCNSL
TBA
Panel Discussion

Session 2: Advances with CAR T-cell therapies 

Saurabh Dahiya
A Phase I study of KITE-753 or KITE-363 in patients with R/R B-cell lymphoma
Saurabh Dahiya Stanford Medicine, Stanford, CA, United States
Jason Westin
Rapcabtagene autoleucel (YTB323) for patients with first line high-risk large B-cell lymphoma
Jason Westin The University of Texas MD Anderson Cancer Center, Houston, TX, United States
Peter Borchmann
Zamtocabtagene autoleucel, a tandem CD20-CD19 directed CAR-T cell therapy, as second-line treatment for R/R LBCL
Peter Borchmann University Hospital Cologne, Cologne, Germany
Panel discussion

Session 3: Latest with bispecifics 

Gilles Salles
Combined mosunetuzumab and zanubrutinib for patients with newly diagnosed high-burden follicular lymphoma
Gilles Salles Memorial Sloan Kettering Cancer Center, New York, NY, United States
Jean-Marie Michot
Odronextamab plus chemotherapy in patients with previously untreated DLBCL: first results from OLYMPIA-3
Jean-Marie Michot Gustave Roussy Institute, Paris, France
Marcel Nijland
Primary Phase III results from Epcore FL-1: epcoritamab with rituximab and lenalidomide (R2) versus R2 for R/R FL
Marcel Nijland University of Groningen Medical Center, Groningen, Netherlands
Panel Discussion

Session 4: Developments with additional immunotherapies and targeted therapies 

Sridhar Chaganti
Initial results of a CRUK Phase I/II, first in human trial of the CAR T-cell engager protein ALETA-001 in patients who have received anti-CD19 CAR T-cell therapy for the treatment of B-cell malignancies
Sridhar Chaganti University of Birmingham, Birmingham, United Kingdom
Jason Westin
Primary analysis of the Smart Stop trial: lenalidomide, tafasitamab, rituximab, and acalabrutinib alone and with combination chemotherapy in newly diagnosed DLBCL
Jason Westin The University of Texas MD Anderson Cancer Center, Houston, TX, United States
Michael Wang
Sonrotoclax (BGB-11417) monotherapy in patients with R/R MCL previously treated with a BTK inhibitor
Michael Wang The University of Texas MD Anderson Cancer Center, Houston, TX, United States
Nirav Niranjan Shah
Bexobrutideg, a novel BTK degrader, shows high clinical activity and tolerable safety in patients with Waldenström's macroglobulinemia
Nirav Niranjan Shah Medical College of Wisconsin, Milwaukee, WI, United States
Panel Discussion

post-ASH 2025 lymphoma highlights webinar supporter copy image

The content of VJHemOnc is intended for healthcare professionals